Genprex, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation TX
Business Address 1601 TRINITY STREET, BLDG. B, AUSTIN, TX, 78712
Mailing Address 1601 TRINITY STREET, BLDG. B, AUSTIN, TX, 78712
Phone 512-537-7997
Fiscal Year End 1231
EIN 900772347
Financial Overview
FY2024
$-5.34
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
Material Events
8-K Other January 9, 2026
High Impact
- Genprex announced positive early (interim Phase 1/2) results for its lead lung cancer drug candidate, REQORSA, showing promising signs in patients.
- The company successfully regained compliance with Nasdaq's minimum stockholders' equity rule, removing an immediate threat of delisting.
8-K Financial Distress December 23, 2025
High Impact
- Genprex, Inc. believes it has successfully raised enough money to meet Nasdaq's minimum stockholders' equity requirement.
- This action aims to avoid delisting from the Nasdaq stock exchange, which was a real possibility.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.